In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.

Department of Immunology and Microbiology 1st Medical Faculty Charles University General Teaching Hospital Prague Karlovo náměstí 32 121 11 Prague 2 Czech Republic

See more in PubMed

Suehiro M, Kishimoto S, Wakabayashi T, et al. Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer. British Journal of Dermatology. 1998;139(4):748–749. PubMed

Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. Journal of the American Academy of Dermatology. 2003;48(3):439–441. PubMed

Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62(3):689–692. PubMed

Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. British Journal of Haematology. 1986;64(1):87–95. PubMed

Bonifazi F, De Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood. 2001;98(10):3074–3081. PubMed

Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine. 2000;6(9):1018–1023. PubMed

Burchert A, Wölfl S, Schmidt M, et al. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101(1):259–264. PubMed

Wu CJ, Yang X-F, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. Journal of Clinical Investigation. 2000;106(5):705–714. PubMed PMC

Chakrabarti D, Hultgren B, Stewart TA. IFN-α induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. Journal of Immunology. 1996;157(2):522–528. PubMed

Tosi D, Valenti R, Cova A, et al. Role of cross-talk between IFN-α-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. Journal of Immunology. 2004;172(9):5363–5370. PubMed

Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. Journal of Clinical Oncology. 1995;13(9):2401–2407. PubMed

Tóthová E, Kafková A, Štecová N, Fričová M, Guman T, Švorcová E. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma. 2002;49(2):91–94. PubMed

Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343–3356. PubMed

Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine. 2002;346(9):645–652. PubMed

Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine. 2001;344(14):1031–1037. PubMed

Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Current Opinion in Hematology. 2004;11(1):35–43. PubMed

Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876–880. PubMed

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401. PubMed

Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer. 2006;94(12):1765–1769. PubMed PMC

Kim PS, Lee PP, Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Computational Biology. 2008;4(6, article no. e1000095) PubMed PMC

Vonka V. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy. 2010;2(2):227–241. PubMed

Humlová Z, Klamová H, Janatková I, et al. Immunologic profiles of patients with chronic myeloid leukemia. I. State before the start of treatment. Folia Biologica (Praha) 2006;52(3):47–58. PubMed

Hamšíková E, Ludvíková V, Šmahel M, Sapp M, Vonka V. Prevalence of antibodies to human Papillomaviruses in the general population of the Czech Republic. International Journal of Cancer. 1998;77(5):689–694. PubMed

Steegmann JL, Moreno G, Aláez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon α and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica. 2003;88(7):762–768. PubMed

Nagasawa M, Mizutani S. Selective effect of imatinib on serum IgM in a patient with CML. International Journal of Hematology. 2004;80(4):381–382. PubMed

Kälsch A-I, Soboletzki M, Schmitt WH, et al. Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? Clinical and Experimental Immunology. 2008;151(3):391–398. PubMed PMC

Minh DQ, Czink E, Mod A, Fust G, Hollan SR. Serial complement measurements in patients with leukaemia. Clinical and Laboratory Haematology. 1983;5(1):23–34. PubMed

Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352(6333):345–347. PubMed

Resnitzky D, Tiefenbrun N, Berissi H, Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(1):402–406. PubMed PMC

Park S-J, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. Journal of Immunology. 2004;173(6):3844–3854. PubMed

Anand M, Chodda SK, Parikh PM, Nadkarni JS. Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukaemia in different stages, and their role in prognosis. Haematological Oncology. 1998;16(4):143–154. PubMed

Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. British Journal of Haematology. 2005;130(5):709–715. PubMed

Du Clos TW, Mold C. C-reactive protein. An activator of innate immunity and a modulator of adaptive immunity. Immunologic Research. 2004;30(3):261–277. PubMed

Szalai AJ. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clinical and Developmental Immunology. 2004;11(3-4):221–226. PubMed PMC

Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HMG, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood. 2003;101(2):545–551. PubMed

Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukaemia in cytogenetic and haematologic remission with interferon-alpha, Clinical and Cancer Research. 2000;6(5):1671–1677. PubMed

Guarini A, Breccia M, Montefusco E, et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. British Journal of Haematology. 2001;113(1):136–142. PubMed

Pawelec G, Rehbein A, Schlotz E, Da Silva P. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunology Immunotherapy. 1996;42(3):193–199. PubMed PMC

Kiani A, Habermann I, Schäkel K, Neubauer A, Rogge L, Ehninger G. Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-α or imatinib. Haematologica. 2003;88(7):754–761. PubMed

Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105(6):2473–2479. PubMed

Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlović S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104(4):1094–1099. PubMed

Gu JJ, Zhang N, He ZW, Koleske AJ, Pendergast AM. Defective T cell development and function in the absence of Abelson kinases. Journal of Immunology. 2007;179(11):7334–7343. PubMed

Sinai P, Berg RE, Haynie JM, Egorin MJ, Ilaria RL, Jr., Forman J. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. Journal of Immunology. 2007;178(4):2028–2037. PubMed

Mumprecht S, Matter M, Pavelic V, Ochsenbein AF. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood. 2006;108(10):3406–3413. PubMed

Chen J, Schmitt A, Giannopoulos K, et al. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. International Journal of Oncology. 2007;31(5):1133–1139. PubMed

Aswald JM, Lipton JH, Aswald S, Messner HA. Increased IFN-γ synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines, Cellular and Molecular Therapy. 2002;7(4):143–149. PubMed

Kynurenine and uric acid levels in chronic myeloid leukemia patients